Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
Christoph
C
Tappeiner
Carsten
C
Heinz
Gerd
G
Ganser
Arnd
A
Heiligenhaus
D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D057915:Drug Substitution; D006801:Humans; D007275:Injections, Intravenous; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab